---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-26-000074"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2026-06-03T22:43:26+00:00"
generated_at: "2026-06-04T10:06:10.457997+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Denali annual meeting results: all director nominees elected, auditor ratified, say-on-pay approved

## Summary
- Elected three Class III directors: Jennifer Cook, David Schenkein, Ryan Watts; broker non-votes ~13.1M.
- Ratified Ernst & Young as auditor for FY2026: 137.5M for, 420K against, 49.6K abstain.
- Non-binding advisory vote on executive compensation approved: 117.0M for, 7.1M against, 717.7K abstain.
- Quorum of 86.96% of outstanding shares (137.99M of 158.68M) represented at meeting.

## SEC filing metadata
- accession: 0001714899-26-000074
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2026-06-03T22:43:26+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000074/0001714899-26-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000074/dnli-20260603.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-26-000074
- JSON: https://secwatch.observer/filing/0001714899-26-000074.json
- Plain text: https://secwatch.observer/filing/0001714899-26-000074.txt

## Key facts
- Shareholder Votes
  Denali Therapeutics Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2026-06-03 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting:
  evidence_url: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000074/0001714899-26-000074-index.htm
- Shareholder Votes
  Denali Therapeutics Inc. shareholders approved Election of three Class III directors at the 2026-06-03 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: Election of three Class III directors to hold office until the 2029 annual meeting of stockholders. Each of the following nominees was elected to serve as a Class III director, to hold office until the Company’s 2029 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000074/0001714899-26-000074-index.htm
- Shareholder Votes
  Denali Therapeutics Inc. shareholders approved Advisory vote to approve executive compensation at the 2026-06-03 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: Advisory Vote to Approve Executive Compensation The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000074/0001714899-26-000074-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.